Alar Pharmaceuticals Stock Book Value Per Share
| 6785 Stock | TWD 146.00 3.50 2.34% |
Alar Pharmaceuticals fundamentals help investors to digest information that contributes to Alar Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Alar Stock. The fundamental analysis module provides a way to measure Alar Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Alar Pharmaceuticals stock.
Alar |
Alar Pharmaceuticals Company Book Value Per Share Analysis
Alar Pharmaceuticals' Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current Alar Pharmaceuticals Book Value Per Share | 10.50 X |
Most of Alar Pharmaceuticals' fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Alar Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
| Competition |
In accordance with the recently published financial statements, the book value per share of Alar Pharmaceuticals is about 10.5 times. This is 717.65% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The book value per share for all Taiwan stocks is 99.46% higher than that of the company.
Alar Book Value Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Alar Pharmaceuticals' direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Alar Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Alar Pharmaceuticals by comparing valuation metrics of similar companies.Alar Pharmaceuticals is currently under evaluation in book value per share category among its peers.
Alar Fundamentals
| Return On Equity | -10.38 | |||
| Return On Asset | -10.09 | |||
| Current Valuation | 2.47 B | |||
| Shares Outstanding | 57 M | |||
| Price To Book | 4.97 X | |||
| Revenue | 600 K | |||
| Gross Profit | 600 K | |||
| EBITDA | (100.27 M) | |||
| Net Income | (64.78 M) | |||
| Cash And Equivalents | 556.12 M | |||
| Cash Per Share | 9.76 X | |||
| Total Debt | 1.07 M | |||
| Debt To Equity | 0 % | |||
| Current Ratio | 97.77 X | |||
| Book Value Per Share | 10.50 X | |||
| Cash Flow From Operations | (71.85 M) | |||
| Earnings Per Share | (2.86) X | |||
| Number Of Employees | 19 | |||
| Market Capitalization | 2.98 B |
About Alar Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Alar Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Alar Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Alar Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Alar Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alar Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alar Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Alar Stock
| 0.88 | 4114 | Synmosa Biopharma | PairCorr |
| 0.74 | 6576 | Foresee Pharmaceuticals | PairCorr |
| 0.85 | 6620 | Handa Pharmaceuticals | PairCorr |
Moving against Alar Stock
| 0.79 | 2345 | Accton Technology Corp | PairCorr |
| 0.59 | 1591 | Inmax Holding | PairCorr |
| 0.56 | 0050 | YuantaP shares Taiwan | PairCorr |
| 0.5 | 1795 | Lotus Pharmaceutical | PairCorr |
| 0.5 | 0057 | Fubon MSCI Taiwan | PairCorr |
The ability to find closely correlated positions to Alar Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Alar Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Alar Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Alar Pharmaceuticals to buy it.
The correlation of Alar Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Alar Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Alar Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Alar Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Alar Stock Analysis
When running Alar Pharmaceuticals' price analysis, check to measure Alar Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alar Pharmaceuticals is operating at the current time. Most of Alar Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alar Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alar Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alar Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.